Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Barbara L. Storer"'
Publikováno v:
Thrombosis Research. 57:967-974
The effects of newly discovered vasoconstrictor peptide endothelin was studied on human, rabbit and canine platelet function. Endothelin (0.01 nM-1 microM) did not promote platelet aggregation. In human platelets, endothelin (0.1 microM) did not sign
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc4247df6281cade501bbd13b40dc9bc
https://doi.org/10.1016/0049-3848(90)90163-7
https://doi.org/10.1016/0049-3848(90)90163-7
Autor:
Giora Z. Feuerstein, Barbara L. Storer, Richard E. Valocik, Paul F. Koster, Michael N. Blackburn, John R. Toomey
Publikováno v:
Thrombosis research. 100(1)
A humanized inhibitory anti-factor IX(a) antibody (SB 249417) has been compared to enoxaparin (Lovenox) in a rat model of arterial thrombosis. Pretreatment of rats with either SB 249417 (3.0 mg/kg, i. v.) or enoxaparin (30.0 mg/kg, i.v. or s.c.) resu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2eed8690b965e92fb350f9c69770d69e
https://pubmed.ncbi.nlm.nih.gov/11053619
https://pubmed.ncbi.nlm.nih.gov/11053619
Publikováno v:
British Journal of Pharmacology. 104:987-989
1. Six weeks following partial nephrectomy in rats, significant increases in serum urea nitrogen and serum creatinine concentration and a significant decrease in creatinine clearance were observed. 2. Measurement of systolic blood pressure by tail pl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fcc91d9cec17e6bf4f3e10396c697e2
https://doi.org/10.1111/j.1476-5381.1991.tb12537.x
https://doi.org/10.1111/j.1476-5381.1991.tb12537.x
Autor:
David P. Brooks, Madelyn M. Caltabiano, Ponnal Nambi, Lisa C. Contino, Eliot H. Ohlstein, Mark Pullen, Barbara L. Storer
Publikováno v:
European Journal of Pharmacology. 194:115-117
The aim of the present study was to determine the effect of a calcium channel blocker on renal function, urinary endothelin excretion and endothelin receptor number in rats. Administration of cyclosporine resulted in a significant impairment of renal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d916f35f11aab85ca0f6f8407f9905e
https://doi.org/10.1016/0014-2999(91)90132-a
https://doi.org/10.1016/0014-2999(91)90132-a
Autor:
Luengo Juan Ignacio, John D. Elliott, Jia-Ning Xiang, Stephanie Guiney, Eliot H. Ohlstein, Robert N. Willette, Barbara L. Storer, Charles F. Sauermelch
Publikováno v:
Journal of cardiovascular pharmacology. 31
Some endothelin (ET) receptor antagonists have been reported to elevate plasma immunoreactive endothelin-1 (irET-1). However, there is no information regarding the effects of ET receptor antagonists on cerebrospinal fluid (CSF) levels. To better unde
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6b2c40a47eb0c734296ff013c721223
https://pubmed.ncbi.nlm.nih.gov/9595425
https://pubmed.ncbi.nlm.nih.gov/9595425
Publikováno v:
Journal of molecular and cellular cardiology. 30(1)
Carvedilol, a multiple action neurohumoral antagonist, has been reported recently to significantly reduce mortality in congestive heart failure (CHF) patients. In addition to being a beta-adrenoceptor antagonist, one of the unique aspects of the biol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::167d7e57627d7f12e31f7d7f608b889c
https://pubmed.ncbi.nlm.nih.gov/9500873
https://pubmed.ncbi.nlm.nih.gov/9500873
Autor:
A. Nichols, J. Samanen, Linda J. Kopaciewicz, Barbara L. Storer, Raul R. Calvo, Janice A. Vasko, Fadia E. Ali, Richard E. Valocik, Todd Romoff
Publikováno v:
Thrombosis research. 75(2)
The properties of SK&F 106760 [N alpha-acetyl-cyclo(S,S)-cysteinyl-N alpha-methyl-arginyl-glycyl-aspartyl-penicillamine-amide] as a GPIIb/IIIa antagonist have been studied in vitro and compared with those of the parent molecule, Ac-RGDS-NH2. Ac-RGDS-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f038539f7459aedb0882010c1353c3dd
https://pubmed.ncbi.nlm.nih.gov/7974388
https://pubmed.ncbi.nlm.nih.gov/7974388
Autor:
Eliot H. Ohlstein, Barbara L. Storer, Ponnal Nambi, Mark Pullen, M.J. Slivjak, Edward F. Smith
Publikováno v:
Pharmacology. 48(3)
The purpose of these studies was to examine the changes in renal endothelin (ET) receptor, renal function and plasma ET (ET-1) concentration in male Sprague-Dawley rats injected with nonlethal doses of Escherichia coli endotoxin (LPS). Prior to the i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17290282275450fe9b0e2117bba9707b
https://pubmed.ncbi.nlm.nih.gov/8153142
https://pubmed.ncbi.nlm.nih.gov/8153142
Autor:
Fadia E. Ali, A. Nichols, Raul R. Calvo, J. Vasko, Barbara L. Storer, D. Bennett, D. Berry, E. Sorenson, Jeffrey M. Stadel, M. Strohsacker, David Powers, J. Samanen, T T Romoff
Publikováno v:
Journal of medicinal chemistry. 34(10)
The development of potent antithrombotic agents from the fibrinogen platelet receptor binding sequences Fg-alpha 572-575 -Arg-Gly-Asp-Ser- and Fg-gamma 400-411 -HHLGGAKQAGDV, believed to be a cryptic RGD-type sequence, is described. The tetrapeptide
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91e9fa52c6c77b6cddbebeec06d31228
https://pubmed.ncbi.nlm.nih.gov/1920361
https://pubmed.ncbi.nlm.nih.gov/1920361
Autor:
Xin L. Ma, Padma K. Narayanan, Eliot H. Ohlstein, Tian-Li Yue, Lynne M. Vickery-Clark, Kent A. Gossett, Robert N. Willette, Barbara L. Storer, Calvert Louden, Xiang Li, Jun Chen, Juan-Li Gu
Publikováno v:
Circulation. 102:III-281
Background—Idoxifene (ID) is a tissue-selective estrogen receptor modulator (SERM). The pharmacological profile of ID in animal studies suggests that it behaves like an estrogen receptor (ER) agonist in bone and lipid metabolism while having neglig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e1697cb062ccc2f4508738abe843efc
https://doi.org/10.1161/01.cir.102.suppl_3.iii-281
https://doi.org/10.1161/01.cir.102.suppl_3.iii-281